Structure via PubChem · Public domain (PubChem)
Galidesivir
Sign in to saveAlso known as BCX 4430, BCX-4430, BCX4430
Galidesivir (BCX4430, immucillin-A) is an antiviral drug, an adenosine analog (a type of nucleoside analog). It was developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease, as well as Zika virus. Currently, galidesivir is under phase 1 human trial in Brazil for coronavirus.
Chemical data
- Formula
- C11H16ClN5O3
- Molecular weight
- 301.73 g/mol
- IUPAC name
- (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol;hydrochloride
- SMILES
- C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O.Cl
- InChIKey
- PCCHVYNGFMEGIG-QPAIBFMUSA-N
- Polar surface area
- 140 Ų
- H-bond donors
- 7
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 301.09416705200005
Show 3 more facts
- chemical formula
- C₁₁H₁₅N₅O₃
- isomeric SMILES
- Cl.N=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12
- canonical SMILES
- Cl.N=c1[nH]cnc2c(C3NC(CO)C(O)C3O)c[nH]c12
via Wikidata · CC0
~2 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Galidesivir (BCX4430, immucillin-A) is an antiviral drug, an adenosine analog (a type of nucleoside analog). It was developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease, as well as Zika virus. Currently, galidesivir is under phase 1 human trial in Brazil for coronavirus.
It also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses, flaviviruses, and phleboviruses. Galidesivir has been demonstrated to protect against both Ebola and Marburg viruses in both rodents and monkeys, even when administered up to 48 hours after infection, and development for use in humans was then being fast-tracked due to concerns about the lack of treatment options for the 2013-2016 Ebola virus epidemic in West Africa.
Excerpted from Wikipedia’s “Galidesivir” article, available under the CC BY-SA 4.0 licence.